To define the transcriptomic signature associated with the FHITlow/pHER2high phenotype, we selected 6 FHITlow/pHER2high cases and 6 other cases in a cohort of primary tumor cells from NSCLC patients whose FHIT and pHER2 status were assessed by western blotting (Supplementary Figure S1). Here, FHIT is linked to neoplasm.